Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Harvard Bioscience ( (HBIO) ) is now available.
On March 6, 2026, Harvard Bioscience, Inc. amended and restated the employment agreement for Chief Executive Officer John Duke, extending his term to July 16, 2027 with automatic two‑year renewals, raising his annual base salary to $515,000 and providing a special $100,000 cash bonus tied to the successful refinancing of the company’s credit facility. The revised deal also increases his variable compensation opportunity through annual cash incentives of up to 80% of base salary, a 2026 target equity grant of 75,000 restricted stock units following a 1‑for‑10 reverse stock split effective March 13, 2026, and enhanced severance and vesting protections upon certain termination or change‑in‑control events.
The board simultaneously strengthened its finance leadership by appointing Mark Frost as Chief Financial Officer and Treasurer effective March 6, 2026, following his service as interim finance chief since April 10, 2025. Frost’s new employment agreement runs to April 10, 2027 with automatic two‑year extensions, sets a $375,000 base salary with up to 60% annual cash incentive eligibility, targets a 2026 equity grant of 30,000 restricted stock units post‑split, and provides structured severance and benefits upon qualifying termination events, signaling the company’s focus on retaining senior executives during a period of capital structure and governance adjustments.
The most recent analyst rating on (HBIO) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and higher leverage) and bearish technicals (below key moving averages with negative MACD). These are partially offset by improving cash flow and debt reduction, a more constructive earnings update with better margins/EBITDA, and corporate actions aimed at refinancing and future cost savings.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. is a life sciences tools company that develops and supplies instruments, systems and related technologies used in preclinical and research applications. Its products support pharmaceutical and biotech companies, academic institutions and other research organizations seeking to advance drug discovery and biomedical innovation.
Average Trading Volume: 440,016
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.73M
For an in-depth examination of HBIO stock, go to TipRanks’ Overview page.